

Apple Health PDL Drug Class Motions

Antidiabetics : Cellular Therapy

- ▶ **Motion:** I move that all products in the Antidiabetics : Cellular Therapy class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Beste**
- ▶ **2nd: Taylor**

Cardiovascular Agents : Misc

- ▶ **Motion:** I move that all products in the Cardiovascular Agents : Misc class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: MacKay**
- ▶ **2nd: Flynn**

Hematopoietic Agents

- ▶ Stem Cell Mobilizers
- ▶ Thrombopoiesis (TPO) Stimulating Proteins

Hematopoietic Agents

Motion: I move that all products in the drug classes listed on slide 4 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in these classes may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: Barkett**
- ▶ **2nd: Weiland**

Asthma and COPD Agents : Monoclonal Antibodies

- ▶ **Motion:** I move that all products in the Asthma and COPD Agents : Monoclonal Antibodies class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: NOT REVIEWED**
- ▶ **2nd:**

ADHD / Anti-Narcolepsy

- ▶ Dopamine And Norepinephrine Reuptake Inhibitors (DNRIS)
- ▶ Non-Stimulants
- ▶ Stimulants - Long Acting
- ▶ Stimulants - Misc
- ▶ Stimulants - Short Acting

ADHD / Anti-Narcolepsy

Motion: I move that all products in the drug classes listed on slide 7 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in these classes may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: NOT REVIEWED**
- ▶ **2nd:**

Antipsychotics / Antimanic Agents

- ▶ Antipsychotics - 2nd Generation
- ▶ Antipsychotics – Combinations
- ▶ Parkinsons Psychotic Disorder
- ▶ Combination Psychotherapeutics

Antipsychotics / Antimanic Agents

Motion: I move that all products in the drug classes listed on slide 9 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in these classes may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: NOT REVIEWED**
- ▶ **2nd:**

Bone Density Regulators : Rank Ligand Inhibitors

- ▶ **Motion:** I move that all products in the Bone Density Regulators : Rank Ligand Inhibitors class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: NOT REVIEWED**
- ▶ **2nd:**

AHDPL Classes

▶ Allergy

- ▶ Allergenic Extracts / Biologicals – Oral

▶ Asthma and COPD Agents

- ▶ Anticholinergics
- ▶ Inhaled Corticosteroid Combinations
- ▶ Inhaled Corticosteroids
- ▶ Long Acting Muscarinic Agent / Long Acting Beta Agonist Combinations
- ▶ Long Acting Muscarinic Agents
- ▶ Phosphodiesterase 4 Inhibitors

AHDPL Classes

- ▶ Endocrine And Metabolic Agents
 - ▶ Growth Hormone Releasing Hormones (GHRH)
- ▶ Hematopoietic Agents
 - ▶ Erythroid Maturation Agents
 - ▶ Erythropoiesis-Stimulating Agents (ESAS)
 - ▶ Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors

AHDPL Classes

▶ Oncology Agents

- ▶ Androgen Biosynthesis Inhibitors - Oral
- ▶ Antiandrogens – Oral
- ▶ Cyclin Dependent Kinases (CDK) Inhibitors – Oral
- ▶ Hedgehog Pathway Inhibitors – Oral
- ▶ MTOR Kinase Inhibitors – Oral
- ▶ Retinoids – Oral
- ▶ Topoisomerase Inhibitors – Oral
- ▶ Antiestrogens – Oral
- ▶ Imidazotetrazines – Oral

AHDPL Classes

- ▶ Respiratory Agents
 - ▶ Pulmonary Fibrosing Agents
- ▶ Smoking Deterrents
 - ▶ Misc – Other

AHDPL Classes

Motion: I move that all products in the drug classes listed on slides 12, 13, 14 and 15 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in these classes may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: NOT REVIEWED**
- ▶ **2nd:**